遗传性额颞叶痴呆的症状发作年龄、死亡年龄与病程:国际回顾性队列研究
该国际回顾性队列纳入3403例来自1492个家庭的GRN、MAPT或C9orf72突变携带者,比较症状发作年龄、死亡年龄和病程。MAPT组发病和死亡最早、病程最长,C9orf72组病程最短;MAPT组变异受特定突变和家族成员影响最大。
要点
- MAPT突变者发病与死亡最早,C9orf72次之,GRN最晚。
- MAPT组病程最长,C9orf72组最短。
- MAPT组发病与死亡年龄变异受特定突变和家族成员影响最大。
核心结论
- 遗传性额颞叶痴呆的症状发作年龄和死亡年龄受遗传组别影响,MAPT突变还受特定突变和家族成员影响。
研究设计与样本
- 国际回顾性队列研究,纳入3403例来自1492个家庭的GRN、MAPT或C9orf72突变携带者,数据来自额颞叶痴呆预防倡议及已发表论文。
关键数值与推荐
- MAPT组发病年龄变异中48%(95%CI 35-62)由特定突变解释,66%(95%CI 56-75)由家族成员解释;死亡年龄变异中61%(95%CI 47-73)由特定突变解释,74%(95%CI 65-82)由家族成员解释。
- GRN组发病年龄变异中2%(95%CI 0-10)由特定突变解释,14%(95%CI 9-22)由家族成员解释;死亡年龄变异中9%(95%CI 3-21)由特定突变解释,20%(95%CI 12-30)由家族成员解释。
- C9orf72组家族成员解释发病年龄变异17%(95%CI 11-26),解释死亡年龄变异19%(95%CI 12-29)。
临床怎么用
- 对MAPT突变携带者,家族成员发病与死亡年龄数据对预估个体发病和死亡年龄尤其有帮助。
- GRN和C9orf72突变携带者的发病与死亡年龄预估需更多考虑其他遗传和环境因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third of cases being genetic. Most of this genetic component is accounted for by mutations in GRN, MAPT, and C9orf72. In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72. METHODS: In this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups and individual mutations. We also assessed correlations between the age at onset and at death of each individual and the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, we used mixed effects models to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried. FINDINGS: Data were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 67 different mutations). Mean age at symptom onset and at death was 49·5 years (SD 10·0; onset) and 58·5 years (11·3; death) in the MAPT group, 58·2 years (9·8; onset) and 65·3 years (10·9; death) in the C9orf72 group, and 61·3 years (8·8; onset) and 68·8 years (9·7; death) in the GRN group. Mean disease duration was 6·4 years (SD 4·9) in the C9orf72 group, 7·1 years (3·9) in the GRN group, and 9·3 years (6·4) in the MAPT group. Individual age at onset and at death was significantly correlated with both parental age at onset and at death and with mean family age at onset and at death in all three groups, with a stronger correlation observed in the MAPT group (r=0·45 between individual and parental age at onset, r=0·63 between individual and mean family age at onset, r=0·58 between individual and parental age at death, and r=0·69 between individual and mean family age at death) than in either the C9orf72 group (r=0·32 individual and parental age at onset, r=0·36 individual and mean family age at onset, r=0·38 individual and parental age at death, and r=0·40 individual and mean family age at death) or the GRN group (r=0·22 individual and parental age at onset, r=0·18 individual and mean family age at onset, r=0·22 individual and parental age at death, and r=0·32 individual and mean family age at death). Modelling showed that the variability in age at onset and at death in the MAPT group was explained partly by the specific mutation (48%, 95% CI 35-62, for age at onset; 61%, 47-73, for age at death), and even more by family membership (66%, 56-75, for age at onset; 74%, 65-82, for age at death). In the GRN group, only 2% (0-10) of the variability of age at onset and 9% (3-21) of that of age of death was explained by the specific mutation, whereas 14% (9-22) of the variability of age at onset and 20% (12-30) of that of age at death was explained by family membership. In the C9orf72 group, family membership explained 17% (11-26) of the variability of age at onset and 19% (12-29) of that of age at death. INTERPRETATION: Our study showed that age at symptom onset and at death of people with genetic frontotemporal dementia is influenced by genetic group and, particularly for MAPT mutations, by the specific mutation carried and by family membership. Although estimation of age at onset will be an important factor in future pre-symptomatic therapeutic trials for all three genetic groups, our study suggests that data from other members of the family will be particularly helpful only for individuals with MAPT mutations. Further work in identifying both genetic and environmental factors that modify phenotype in all groups will be important to improve such estimates. FUNDING: UK Medical Research Council, National Institute for Health Research, and Alzheimer's Society.
引用
- Moore KM, Nicholas J, Grossman M, et al. Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol. 2019. PMID: 31810826. doi:10.1016/S1474-4422(19)30394-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。